Table 3.
Biochemical analysis and blood count profiles of the subjects before and after the intervention.
| Characteristics | Items | Before | After | ||
|---|---|---|---|---|---|
| Placebo | Ex PLUS® | Placebo | Ex PLUS® | ||
| Biochemistry parameters |
AST (U/L) | 24±5 a | 23±5 a | 24±4 a | 23±5 a |
| ALT (U/L) | 14±4 a | 14±3 a | 14±4 a | 14±3 a | |
| ALB (g/dL) | 5.15±0.33 a | 5.15±0.30 a | 5.20±0.24 a | 5.17±0.30 a | |
| TC (mg/dL) | 191±20 a | 193±25 a | 193±20 a | 193±25 a | |
| TG (mg/dL) | 54±14 a | 57±16 a | 57±13 a | 57±16 a | |
| HDL (mg/dL) | 67.6±6.2 a | 67.2±6.2 a | 68.3±5.8 a | 67.5±5.5 a | |
| LDL (mg/dL) | 94.6±12.6 a | 95.2±12.6 a | 95.6±12.4 a | 95.6±12.2 a | |
| BUN (mg/dL) | 15.7±2.6 a | 15.3±2.7 a | 15.8±2.4 a | 15.4±2.8 a | |
| CREA (g/dL) | 1.10±0.11 a | 1.08±0.12 a | 1.11±0.10 a | 1.09±0.12 a | |
| UA (mg/dL) | 5.2±1.0 a | 5.2±1.1 a | 5.3±1.0 a | 5.2±1.1 a | |
| Glucose (mg/dL) | 81±6 a | 83±7 a | 82±6 a | 83±7 a | |
| CBC | WBCs (103/mcL) | 5.9±0.9 a | 5.9±0.8 a | 6.1±0.8 a | 6.2±0.8 a |
| Neutrophils (%) | 54.7±5.3 a | 54.1±6.7 a | 54.5±6.2 a | 53.9±8.9 a | |
| Lymphocytes (%) | 34.2±4.4 a | 34.7±6.6 a | 35.0±5.1 a | 35.3±8.7 a | |
| Monocytes (%) | 7.5±1.4 a | 7.3±1.4 a | 7.0±1.7 a | 7.0±1.5 a | |
| Eosinophils (%) | 3.0±1.8 a | 3.0±2.2 a | 3.2±2.0 a | 2.7±1.9 a | |
| Basophils (%) | 0.7±0.2 a | 0.8±0.4 a | 0.7±0.3 a | 0.8±0.4 a | |
| Platelets (103/mcL) | 260±33 a | 262±36 a | 251±44 a | 255±39 a | |
Data are shown as the mean ± SD. Statistical significance between the Placebo and Ex PLUS® groups at the same collection time points was analyzed using Student's unpaired t-test. The same superscript letter (a) indicates no significant differences among the groups at p > 0.05. AST, aspartate aminotransferase; ALT, alanine aminotransferase; BUN, blood urea nitrogen; CREA, creatine; UA, uric acid; TP, total protein; TC, total cholesterol; TG, triacylglycerol. HDL, high-density lipoprotein; LDL, low-density lipoprotein; WBC, white blood cell.